Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Enterprise Value (2016 - 2026)

Champions Oncology has reported Enterprise Value over the past 17 years, most recently at -$7.0 million for Q1 2026.

  • For Q1 2026, Enterprise Value fell 118.77% year-over-year to -$7.0 million; the TTM value through Jan 2026 reached -$7.0 million, down 118.77%, while the annual FY2025 figure was -$9.8 million, 273.76% down from the prior year.
  • Enterprise Value for Q1 2026 was -$7.0 million at Champions Oncology, up from -$8.5 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$2.6 million in Q2 2024 and troughed at -$10.8 million in Q4 2022.
  • A 5-year average of -$6.3 million and a median of -$5.5 million in 2023 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: skyrocketed 50.05% in 2024 and later crashed 273.76% in 2025.
  • Year by year, Enterprise Value stood at -$10.8 million in 2022, then soared by 49.08% to -$5.5 million in 2023, then soared by 50.05% to -$2.8 million in 2024, then tumbled by 207.01% to -$8.5 million in 2025, then rose by 17.15% to -$7.0 million in 2026.
  • Business Quant data shows Enterprise Value for CSBR at -$7.0 million in Q1 2026, -$8.5 million in Q4 2025, and -$10.3 million in Q3 2025.